Arcadia Biosciences (RKDA) Stock
Niche agricultural developer licensing improved crop traits. Here's the price, business snapshot, and what's worth knowing about Arcadia Biosciences in October 2026.
Arcadia Biosciences Inc (RKDA) is a small, niche agricultural biotechnology company focused on developing crop traits and seed technologies intended to improve nutrition, stress tolerance and yield potential. Its business historically relies on research, intellectual property and licensing agreements with seed companies and food producers rather than large-scale commercial farming operations of its own. For investors this means potential upside from successful trait adoption or licence deals, but also material risks: RKDA’s very small market capitalisation implies limited liquidity, and revenues can be irregular and dependent on partners, regulatory approvals and commodity cycles. Research-stage assets in agriculture face technical, regulatory and commercial hurdles. Before considering exposure, check the company’s recent filings, partnership announcements, cash position and patent positions. This summary is educational only and not personalised investment advice; small-cap biotech/agricultural stocks can be highly volatile and investors should be prepared for losses.
Arcadia Biosciences (RKDA) Stock Forecast
Analyst price target, next 12 months
$12.00
+7325.7% vs today's $0.16
Price range over the last 12 months
Close to its 12-month low
Analysts covering Arcadia Biosciences have a consensus 12-month target of $12.00, above the current price of $0.16.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Arcadia's stock with a target price of $12, indicating strong growth potential.
Financial Health
Arcadia Biosciences is generating modest revenue and cash flow, but has a low book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Licence & Royalties
Revenue often comes from licences and royalties on trait technologies; partnership deals can be value catalysts, though income may be uneven and uncertain.
Crop Trait Potential
Focus on traits such as stress tolerance and improved nutrition addresses global food challenges, but adoption depends on approvals, farmer uptake and market acceptance.
Small‑Cap Risks
A very small market capitalisation signals low liquidity and higher volatility; expect potential dilution and binary outcomes with research‑stage assets.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
